# US 2026/0295109 A1 · Packaging Solution Comprising Collagen Fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0295109 A1
- Document ID: US20260295109A1
- Status: Published application
- Kind: A1
- Application number: 19/570,382
- Filed: 2026-03-18
- Published: 2026-10-01
- Earliest claimed: 2025-03-19
- Assignees: Bausch + Lomb Ireland Limited
- Applicants: Bausch + Lomb Ireland Limited
- Inventors: Jade J. Russell; Alok K. Awasthi; James Anthony DiBella
- Web page: https://patentgrep.com/patent/US20260295109A1

## CPC

- A61L 12/14: Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L 12/086: {Container, accessories or devices therefor}
- G02C 7/049: {Contact lenses having special fitting or structural features achieved by special materials or material structures}
- A61L 2101/46: Macromolecular compounds
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- G02C: SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES (trial frames for testing the eyes A61B3/04; goggles or eyeshields not having the same features as spectacles A61F9/00)

## Abstract

The present invention relates to ophthalmic devices, in particular contact lenses, which are capable of gradually releasing one or more collagen fragments during wear. The present invention also provides methods for making ophthalmic devices of the invention and for using time-controlled release of one or more collagen fragments for improving comfort and/or treating eye conditions, such as dry eye disease.

## Claims

### Claim 1

A packaged contact lens comprising an unworn sterile contact lens immersed in a packaging solution and sealed in a container, wherein the packaging solution comprises one or more collagen fragments.

### Claim 2 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragments have an average molecular weight of 1 to 7 kDa and a molecular weight in the range from 0.1 to 13.5 kDa.

### Claim 3 (depends on 2)

The packaged contact lens of claim 2, wherein the collagen fragment is from about 0.001% to about 20% by weight of the packaging solution.

### Claim 4 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragments are derived from the group of amino acid sequences consisting of collagen type VI, Col1A1, Col1A2, and Col3A1.

### Claim 5 (depends on 4)

The packaged contact lens of claim 4, wherein the collagen fragment is from about 0.001% to about 20% by weight of the packaging solution.

### Claim 6 (depends on 5)

The packaged contact lens of claim 5, wherein said collagen fragments are derived from collagen type VI.

### Claim 7 (depends on 6)

The packaged contact lens of claim 6, wherein said collagen fragments are derived from the group of amino acid sequences consisting of the α2 chain of collagen type VI, the α3 chain of collagen type VI, the α4 chain of collagen type VI, the α5 chain of collagen type VI, and the α5 chain of collagen type VI.

### Claim 8 (depends on 7)

The packaged contact lens of claim 7, wherein said collagen fragments comprise an intact VWA domain.

### Claim 9 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragment has the amino acid sequence of SEQ ID NO: 1.

### Claim 10 (depends on 9)

The packaged contact lens of claim 9, wherein the collagen fragment is from about 0.001% to about 20% by weight of the packaging solution.

### Claim 11 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragment has an amino acid sequence with at least about 70% sequence identity to SEQ ID NO: 1.

### Claim 12 (depends on 11)

The packaged contact lens of claim 11, wherein said collagen fragment has a molecular weight from about 40 kDa to about 60 kDa.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragment has the amino acid sequence of SEQ ID NO: 2.

### Claim 16 (depends on 1)

The packaged contact lens of claim 1, wherein said collagen fragment has an amino acid sequence with at least about 70% sequence identity to SEQ ID NO: 2.

### Claim 17 (depends on 16)

The packaged contact lens of claim 16, wherein said collagen fragment has an average molecular weight from about 40 kDa to about 60 kDa.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

An ophthalmic product comprising a sealed package which comprises a packaging solution and a contact lens, wherein the packaging solution comprises a collagen fragment.

### Claim 21 (depends on 20)

The ophthalmic product of claim 20, wherein said contact lens has a lower mean static COF when measured unrinsed than when measured rinsed.

### Claim 22 (depends on 20)

The ophthalmic product of claim 20, wherein said contact lens has a lower mean low kinetic COF when measured unrinsed than when measured rinsed.

### Claim 23 (depends on 20)

The ophthalmic product of claim 20, wherein said contact lens has a lower high kinetic COF when measured unrinsed than when measured rinsed.

### Claim at position 24

-30. (canceled)
